HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • Will Improving Adherence Optimize Medication Use?
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / Archives for Featured

ICER Publishes Final Evidence Report on Digital Therapeutics for Opioid Use Disorder

ICER Publishes Evidence Report on Digital Therapeutics for Opioid Use Disorder The Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of three digital health technologies (DHTs) […]

more info 12/11/2020View Related Articles
Bookmark and Share

Cystic Fibrosis Drug Pricing Violates Human Rights According to Patients

In an unusual move, a coalition of cystic fibrosis patients and their families have filed a complaint with the United Nations, arguing that Vertex Pharmaceuticals (VRTX) is harming patient rights through prohibitive pricing and distribution policies for its life-saving medicines. Specifically, […]

more info 12/11/2020View Related Articles
Bookmark and Share

[On-demand Video] Secondary Data First

Secondary data sourced from routinely collected healthcare information is playing a decisive role in stakeholder decision making. Learn how this data is accessed today, which database is right for your purposes, and the key steps to consider to optimize your studies from planning to execution. In […]

more info 12/10/2020View Related Articles
Bookmark and Share

COVID-19 and Influenza to be Initial Focus of Google Health Studies App

Google is upping its focus on health research with a new mobile app that lets smartphone users participate in virtual health studies. The tech giant announced Wednesday its new Google Health Studies app with an initial focus on respiratory illnesses, including influenza and COVID-19. The new Google […]

more info 12/10/2020View Related Articles
Bookmark and Share

Trump’s Last Ditch Effort to Change Rx Price Rules

The Trump administration’s 11th hour attempt to bring down high prescription drug costs succeeded in drawing swift condemnation from health care stakeholders who frequently find themselves at odds. The finalization last month of two rules intended to ease the financial burden on patients was […]

more info 12/10/2020View Related Articles
Bookmark and Share

What’s Driving Oncology HTAs in South Korea?

Reimbursement in South Korea depends upon a favorable review by Health Insurance Review Agency (HIRA), and some therapies may not be reimbursed because of shortcomings from the perspective of HIRA. To help pharma companies plan clinical trials and economic evidence submission in order to achieve […]

more info 12/10/2020View Related Articles
Bookmark and Share

Google Launches Health Studies App

Google made a major move into health research on Wednesday, unveiling a new smartphone app that lets Android users participate in medical studies remotely. The app, called Google Health Studies, could enable the tech giant to better position itself against competitor Apple, which has rolled out […]

more info 12/10/2020View Related Articles
Bookmark and Share

Outrage Over Google’s Firing of AI Ethicist Timnit Gebru

Google abruptly fired Timnit Gebru last night, an AI ethicist who has tremendous respect around the world for her work on racial bias in algorithms. Gebru, who was the co-lead of Google’s ethical AI team, announced her firing in a series of tweets on Wednesday. The news was immediately met with […]

more info 12/10/2020View Related Articles
Bookmark and Share

Reshaping of Global Policy by COVID: Implications for Market Access

The COVID-19 pandemic has upended daily lives around the globe and has also created new challenges for life sciences companies and governments alike in their mission to ensure effective treatments are both developed and available to patients in need. At a time of uncertainty, governments around the […]

more info 12/09/2020View Related Articles
Bookmark and Share

Virtual ISPOR 2021 Issue Panel & Workshop Proposals Due Next Week!

Submit by Wednesday, December 16 for an Opportunity to Present Your Research at Virtual ISPOR 2021! Due to the constraints of the current global environment, ISPOR has extended the deadline for issue panel and workshop proposals to December 16 to allow those interested in speaking at Virtual ISPOR […]

more info 12/09/2020View Related Articles
Bookmark and Share

Delays in Clinical Trials Present Pharma Companies With Opportunities to Evolve

COVID-19 has upended clinical trial timelines – putting billions of forecasted sales at risk and delaying getting life-saving treatments to patients. This analysis from Garima Kaul, Senior Director, Research and Insights, Decision Resources Group, part of Clarivate, and Jamie Munro, Executive […]

more info 12/09/2020View Related Articles
Bookmark and Share

[Webinar] Tumor Profiling for Health Insurance Providers

On December 10, 2020  1:00 PM – 2:00 PM ET, Illumina will host a webinar on comprehensive genomic profiling (CGP). CGP of tumors is an important aspect of determining therapy for individuals with advanced cancer. It is covered by Medicare for patients with advanced cancers seeking further cancer […]

more info 12/09/2020View Related Articles
Bookmark and Share

Using Real World Data to Close the Rare Disease Gap

7,000. That’s the estimated number of distinct types of rare and genetic diseases affecting more than 400 million people around the world. Yet 95% of rare diseases lack an FDA-approved product for treatment.1 Even with the Orphan Drug Act, there are many daunting barriers that stand between […]

more info 12/09/2020View Related Articles
Bookmark and Share

[Webinar] Setting the Agenda for #46

On December 9, 4pm CST, Optum will host a webinar focusing on healthcare-related issues that will be in the forefront in the next few months as President Donald Trump looks to leave his mark through executive orders, the Supreme Court considers the fate of the Affordable Care Act and Congress […]

more info 12/09/2020View Related Articles
Bookmark and Share

Data on a Mission: Removing Barriers to Understanding of Rare Disease

Research and drug development for rare and genetic diseases is challenging without insight into history and clinical manifestations. Missing efficacy endpoints and underrepresentation in medical coding systems further hinder our understanding of rare disease. Real-world data (RWD) closes this data […]

more info 12/08/2020View Related Articles
Bookmark and Share

Healthcare Artificial Intelligence Market: Global Forecast to 2027

Report Highlights: The global healthcare artificial intelligence (AI) market is expected to grow at a CAGR of 41.4% from 2020 to 2027 to reach $51.3 billion by 2027. The healthcare artificial intelligence market study presents historical market data in terms of value (2019), estimated […]

more info 12/08/2020View Related Articles
Bookmark and Share

Six Payer Executives to Watch in 2021

The past year has forced health plans to nimbly adapt to the demands of a global pandemic, including massive spikes in demand for telehealth and new therapies—and soon, vaccines—coming to market. These changes, especially the now-larger market for virtual visits and digital care, are likely to carry […]

more info 12/08/2020View Related Articles
Bookmark and Share

Improving Peer Review in Economics

Three experimental economists, Gary Charness (UCSB), Anna Dreber (SSE) and Severine Toussaert (Oxford), are conducting a 15-20 min anonymous survey on peer review in economics. So far, more than 1,000 researchers have completed the survey and they would like to invite you to participate if you […]

more info 12/07/2020View Related Articles
Bookmark and Share

Response to NICE Methods of Health Technology Evaluation

NICE recently posted a consultation entitled "The NICE methods of health technology evaluation: the case for change". which detailed its proposals for reviewing and/or updating its methods. It sets out 5 areas of work with 56 separate proposals listed separately across these sections. These […]

more info 12/07/2020View Related Articles
Bookmark and Share

New Healthcare Venture from Uber Health’s Dan Trigub

Trigub and co-founder Inna Plumb have launched MedArrive as a new care management platform that enables healthcare providers and payers to extend services into the home. The startup bridges the virtual care gap by integrating physician-led telemedicine with hands-on care from a network of trusted […]

more info 12/04/2020View Related Articles
Bookmark and Share

ICER Analytics™ Accelerates Real-World Application of ICER Reports

The Institute for Clinical and Economic Review (ICER) today formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices, and explore new ways to apply […]

more info 12/04/2020View Related Articles
Bookmark and Share

Disruption and Transformation in the COVID Era: 5 Pharma Trends for 2021

The prospective pharmaceutical industry trends first identified by Tribeca Knowledge in late 2019 were all pre-COVID, even though they continue to unfold. Now, the COVID-19 pandemic has eclipsed every other development in healthcare and pharmaceuticals during 2020. It will likely do so next year as […]

more info 12/04/2020View Related Articles
Bookmark and Share

AMCP Nexus 2020: The Specialty Pharmacy Pipeline

The specialty pharmaceutical market is continuing to see increased competition, and in the past 10 years, there has been a significant number of new options to treat patients with several specialty conditions. During a session at AMCP Nexus 2020 Virtual, Aimee Tharaldson, PharmD, senior clinical […]

more info 12/04/2020View Related Articles
Bookmark and Share

Innovative Payments, Management are Needed for Cell and Gene Therapies

Cell and gene therapies are a transformative approach that provides new therapeutic options for patients with cancer, immune disorders, hemophilia, and other conditions. However, these therapies present fundamental challenges for payers seeking to balance access, cost, and affordability. During a […]

more info 12/04/2020View Related Articles
Bookmark and Share

MMIT Partners With Leading Patient Access Hubs

Understanding market access is hard. Tracking shifts in coverage and payer policies for pharmaceutical products is even harder. MMIT partners with leading patient access hubs to provide them with a competitive advantage, supported by the industry leader in patient access information and insights. […]

more info 12/03/2020View Related Articles
Bookmark and Share

Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?

Little is known about when and what types of real-world evidence (RWE) studies inform pharmacy and therapeutic (P&T) committee decisions. To address this gap in knowledge, researchers evaluated evidence sources cited in P&T committee monographs and therapeutic class reviews and assessed the […]

more info 12/03/2020View Related Articles
Bookmark and Share

CMS Announces Drug Payment Reductions with the “Most Favored Nation” Effective January 1, 2021

Centers for Medicare and Medicaid Services (CMS) announced the long-awaited seven year Most Favored Nation (MFN) model as an interim final rule. Published in the Federal Register on Nov. 27, the rule will potentially decrease payment for 50 expensive drugs provided in hospital outpatient departments […]

more info 12/03/2020View Related Articles
Bookmark and Share

Reimbursing Innovative and Potentially Curative Gene and Cell Therapies

In this feature, following his participation in a workshop at the International Society for Pharmacoeconomics and Outcomes Research’s 2020 Asia Pacific meeting (Virtual ISPOR Asia Pacific 2020; 14–16 September), Sean Sullivan (University of Washington, WA, USA) discusses payment approaches that […]

more info 12/03/2020View Related Articles
Bookmark and Share

Government, Big Pharma, and The People: A Century of Dis-Ease

It can be said that society shapes our values toward drugs and drugs shape society. And while drug prices are at the forefront of many voters’ minds, they are not actually the main reason the U.S. spends so much on health care. Even though pharmaceuticals account for a relatively small share of […]

more info 12/03/2020View Related Articles
Bookmark and Share

Biden Defers to Experts on COVID-19 Vaccine Prioritization

There will likely be a limited supply of coronavirus vaccine doses available immediately after a vaccine is authorized by the US Food and Drug Administration, and because risk for Covid-19 can vary among different groups of people, prioritizing the vaccine poses challenges. Therefore, […]

more info 12/02/2020View Related Articles
Bookmark and Share

  • Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 116
  • Next Page

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • Optimizing Patient Recruitment: Download Whitepaper
  • How Healthcare Providers and Payers Drive Outcome-Based Analytics
  • New Primer and Ebook on Synthetic Control Arms
  • Get Drugs & Devices to Market Faster
       Drugs & Devices to Market Faster with 21 CFR Part 11 Compliance
  • COVID-19 is impacting HTA priorities and processes
  • Leveraging Simulation to Patch a Clinical Trial Broken by COVID-19
  • A Systematic Approach to Assessing Real-World Research Questions Supported by Digital Enablement
  • Version 4.1 of the AMCP Format: Introducing a Trio of Dossiers to Support a Product Throughout its Lifecycle
  • Patient Preference Studies in HTA Decision Making: A NICE to Have?
  • Trends in Medical Device Purchasing, Evaluation of Value, and Advice for Manufacturers
  • Integrated Scientific Advice during the COVID-19 Pandemic
  • US FDA’s Emergency Use Authorization (EUA): Applicability for Marketed and/or Investigational Products for Treatment of COVID-19
  • Surprises You Don’t Want When Adopting eCOAs for Use in Clinical Trials: Cautions for Decision Making and Planning
  • Digital Approaches in the Era of COVID-19: Interviews with Science 37 and Medable
  • Evidence Generation Using Innovative, Technology-Driven Data Collection
  • Digital Therapeutics: Past Trends and Future Prospects
  • Leveraging Decentralized RWE Data Collection Strategies during the COVID-19 Pandemic and Beyond
  • The Potential Impact of Pharmaceutical and Non-Pharmaceutical Interventions to Mitigate the COVID-19 Crisis in the United States: A Model-Based Analysis
  • How to make quality metrics work for you
  • eBook: 2020-2030 | Reimagining Healthcare IT for the Next Decade
  • ISPOR Value of Information Task Force Publishes Two New Good Practices Reports
  • The Convergence of Data Analytics and Artificial Intelligence (AI) in Healthcare
  • Artificial Intelligence and Machine Learning
  • Prescription Price Transparency And The Patient Experience
  • Developing medical communications specifically for nurses
  • Protocol Design in Real-World Evidence: The Indispensable Link Between Strategic Need and Study Execution
  • Health Economics in China: Changing Pharmaceutical Pricing and Reimbursement
  • The Growing Influence of the Institute of Clinical and Economic Review on Payer Decisions in the US
  • Research Operations for Secondary Use of Clinical Sites’ EMR
  • The Role of Integrated Scientific Advice for the Early Determination of RWE Requirements in HTA and Payer Assessments

Syndicated Reports

  • Biosimilars: US Payer Perspectives
  • KAM Metrics: Driving Efficiency, Measuring Success
  • Biosimilars: E.U. Payer Perspectives
  • MSL Teams: Field Force Size and Structure
  • Market Access Impact: Type 2 Diabetes Mellitus (Injectables) (US) 2017
  • Market Access Impact: Type 2 Diabetes Mellitus (Orals) (US) 2017
  • Market Access Impact: Rheumatoid Arthritis (US) 2017
  • Pricing and Reimbursement in Oncology: Payer views
  • The ROI of Orphan Drugs: Ensuring Optimal Returns
  • New Syndicated Report – Orphan Drug Launch Strategies: Case Studies
  • New Syndicated Report: 2017 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
  • Market Access Team Structure and Function: Industry Survey 2017
       New syndicated report available
  • Patient-Centered Risk Assessments – A Key Ingredient of Value-based Care
       New white paper by Sandra Hewett
  • The Future of Market Access in the U.S.
  • New Syndicated Report: The Future of Market Access in Europe
  • Syndicated Report: Biomarkers and Companion Diagnostics — Payer views
  • Syndicated Report: Why Pharma Needs to Get Serious about Data
  • Syndicated Report Available: How Payers Want to Work with Pharma
  • Syndicated report: The Future of Biosimilars in Europe
  • Syndicated report: World Preview 2017, Outlook to 2022
  • How Can MSL Performance be Measured Effectively?
  • Medical Writing: The Backbone of Clinical Development
  • The Future of Medical Affairs
  • Value-Based Healthcare: Making it Happen
  • Pricing and Market Access – Facts Versus Fiction
  • Is Your Market Access Team Making the Most of Real World Data Yet?
  • How Will Pricing Wars Shape the RA Landscape?
  • Benchmarking Biologic Innovator Value-Added-Services
  • Payer Insights on Orphan Drug Market Access
  • What do Payers Really Think About the Rising Cost of Specialty Drugs?
HealthEconomics.Com

HealthEconomics.Com

  • Become a Better Writer!
  • HealthEconomics.Com Recognized as Top Influencer at ISPOR International Meeting in Washington DC
  • Will ICER Framework Destroy Progress Against Multiple Myeloma?
  • Celgene Unleashes the Power of Data into Clinical Trial Design
  • How Well is Harvoni Working in the Real World?
  • New CVS and Express Scripts Value Based Plans for Oncology
  • Oversized Cancer Drug Vials Waste $3B Each Year
  • Can More Data Make Providers’ Jobs Easier?
  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Take This Survey for a Chance to Win $200!
  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • ICER Releases Two Draft Reports on Obeticholic Acid
  • What do Patient Advocates Think of New ICER Report?
  • Could a New ICER Report Put Patients at Risk?
  • Contact Us

About

  • International Myeloma Foundation Responds to ICER Report
  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • Doctor Evidence Launches GROWTH Replicator Program
  • Is PCORI Underfunding CER?
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • Will Improving Adherence Optimize Medication Use?
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute